Integra LifeSciences Holdings Corporation reported first‑quarter 2026 results on May 5, 2026, delivering revenue of $391.9 million, up 2.4 % year‑over‑year, and an adjusted earnings per share of $0.54. The $0.54 adjusted EPS beat the consensus estimate of $0.41 by $0.13, a 31.7 % overrun, while revenue surpassed the $381.81 million estimate by $10.09 million, a 2.6 % beat.
Segment‑level data show that Tissue Reconstruction grew 6.7 % reported and 6.4 % organic, driven by strong demand for Integra Skin and the relaunch of PriMatrix® and Durepair®. Specialty Surgery was essentially flat, with a 0.9 % reported increase but a 0.6 % organic decline, reflecting timing headwinds in some product lines. The company’s Braintree manufacturing facility made progress toward production of SurgiMend®, expected to begin by the end of June.
Adjusted EBITDA margin expanded to 19.4 % from 16.6 % a year earlier, a 2.8‑percentage‑point lift attributed to disciplined cost‑control initiatives and favorable tariff impacts under the IEEPA. Improved supply reliability also helped stabilize costs, while the company’s focus on operational rigor has begun to translate into higher profitability.
Management reaffirmed full‑year 2026 revenue guidance of $1.66 billion to $1.70 billion and raised adjusted EPS guidance to $2.40 to $2.50 from $2.30 to $2.40, signaling confidence that the current momentum and cost efficiencies will carry through the year. The company’s net debt remains at $1.60 billion, with a leverage ratio of 4.1×, and free cash flow was negative but improved year‑over‑year.
Stuart Essig, Chairman and Chief Executive Officer, said, “Our first‑quarter results reflected solid product demand and the continued impact of our transformation efforts. We are seeing improving performance across the organization as operational rigor and improved execution take hold.” He added, “During the quarter, we continued to drive improved supply reliability, supporting strong growth in Integra Skin and our return to market with PriMatrix® and Durepair®. We made meaningful progress at our state‑of‑the‑art Braintree manufacturing facility and remain on track to begin production of SurgiMend® by the end of June to support a fourth quarter launch. Building on these efforts, we are focused on maintaining disciplined execution and remain confident in our ability to deliver our full‑year commitments to our customers, patients, and shareholders.”
The market reacted strongly, with Integra LifeSciences shares surging 16.2 % in pre‑market trading. The rally was driven by the EPS and revenue beats, the margin expansion, and the raised EPS guidance, all of which underscored the company’s improving execution and the effectiveness of its transformation program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.